REIN THERAPEUTICS INC (RNTX) Stock Price, Quote, News and Overview
NASDAQ:RNTX - Nasdaq - US00887A2042 - Common Stock - Currency: USD
RNTX Quote, Performance and Key Statistics
NASDAQ:RNTX (7/17/2025, 8:00:02 PM)
1.4
-0.04 (-2.78%)
The current stock price of RNTX is 1.4 USD. In the past month the price decreased by -22.22%.
RNTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.64 | 338.09B | ||
| AMGN | AMGEN INC | 14.37 | 160.37B | ||
| GILD | GILEAD SCIENCES INC | 14.06 | 135.34B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.41 | 59.38B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 42.34B | ||
| ARGX | ARGENX SE - ADR | 99.6 | 34.97B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.43 | 31.42B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.69B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.52B | ||
| INSM | INSMED INC | N/A | 19.76B | ||
| NTRA | NATERA INC | N/A | 19.58B |
Related stock screener links
About RNTX
Company Profile
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. The company is headquartered in Austin, Texas and currently employs 11 full-time employees. The company went IPO on 2017-06-29. The firm's lead product candidate, LTI-03 (idiopathic pulmonary fibrosis), is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Its second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the United States and European Union and Fast Track Designation in the United States. Its pipeline also includes LTI-05 (cystic fibrosis).
Company Info
REIN THERAPEUTICS INC
12407 N. Mopac Expy., Suite 250 #390
Austin TEXAS US
Employees: 11
Phone: 17378021989
REIN THERAPEUTICS INC / RNTX FAQ
What is the stock price of REIN THERAPEUTICS INC today?
The current stock price of RNTX is 1.4 USD. The price decreased by -2.78% in the last trading session.
What is the ticker symbol for REIN THERAPEUTICS INC stock?
The exchange symbol of REIN THERAPEUTICS INC is RNTX and it is listed on the Nasdaq exchange.
On which exchange is RNTX stock listed?
RNTX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REIN THERAPEUTICS INC stock?
7 analysts have analysed RNTX and the average price target is 7.14 USD. This implies a price increase of 410% is expected in the next year compared to the current price of 1.4. Check the REIN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REIN THERAPEUTICS INC worth?
REIN THERAPEUTICS INC (RNTX) has a market capitalization of 31.01M USD. This makes RNTX a Nano Cap stock.
How many employees does REIN THERAPEUTICS INC have?
REIN THERAPEUTICS INC (RNTX) currently has 11 employees.
What are the support and resistance levels for REIN THERAPEUTICS INC (RNTX) stock?
REIN THERAPEUTICS INC (RNTX) has a support level at 1.39 and a resistance level at 1.56. Check the full technical report for a detailed analysis of RNTX support and resistance levels.
Should I buy REIN THERAPEUTICS INC (RNTX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RNTX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RNTX, evaluating the profitability, health, valuation and growth aspects
- REIN THERAPEUTICS INC (RNTX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REIN THERAPEUTICS INC (RNTX) Sales and EPS estimates to see what analysts future expectations are.
- REIN THERAPEUTICS INC (RNTX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REIN THERAPEUTICS INC (RNTX) Insider and Institutional Ownership to learn about the owners and their transactions.
- REIN THERAPEUTICS INC (RNTX) Stock Chart to make your own analysis
- REIN THERAPEUTICS INC (RNTX) Latest news and press-releases to stay up to date.
Does REIN THERAPEUTICS INC (RNTX) stock pay dividends?
RNTX does not pay a dividend.
When does REIN THERAPEUTICS INC (RNTX) report earnings?
REIN THERAPEUTICS INC (RNTX) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of REIN THERAPEUTICS INC (RNTX)?
REIN THERAPEUTICS INC (RNTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.17).
What is the Short Interest ratio of REIN THERAPEUTICS INC (RNTX) stock?
The outstanding short interest for REIN THERAPEUTICS INC (RNTX) is 0.29% of its float. Check the ownership tab for more information on the RNTX short interest.
RNTX Technical Analysis
RNTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RNTX. While RNTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
RNTX Financial Highlights
Over the last trailing twelve months RNTX reported a non-GAAP Earnings per Share(EPS) of -3.17.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -28.06% | ||
| ROE | -30.71% | ||
| Debt/Equity | 0 |
RNTX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to RNTX. The Buy consensus is the average rating of analysts ratings from 7 analysts.